Advertisement

Genetic Engineering of Death Ligands for Improvement of Therapeutic Activity

  • Jeannette Gerspach
  • Britta Schneider
  • Nicole Müller
  • Tina Otz
  • Harald Wajant
  • Klaus Pfizenmaier
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 691)

Abstract

The death ligands TRAIL, FasL/CD95L, and TNF are in the focus of intense preclinical and clinical research efforts having the aim to exploit these molecules as new anticancer drugs. A common feature of these ligands is that their transmembrane form displays higher and/or broader activity than their soluble counterpart. Accordingly, the bioactivity of the soluble form of these ligands ranges from being poorly active (FasL/CD95L) to displaying a receptor type-selective signaling capacity (TNF, TRAIL). The presently approved or clinically exploited recombinant variants of TNF and TRAIL correspond to the soluble trimeric form of these proteins. In order to increase their intrinsic and tumor-selective bioactivity, we modified these ligands by genetic engineering to reach two aims: (i) stabilization of their trimeric organization and/or (ii) directing ligand action to the diseased tissue. Here, we summarize our concepts and show recent data on improving death ligand activity by intramolecular stabilization and/or membrane ligand mimicking activity through cell surface presentation.

Keywords

Fusion Protein HT1080 Cell Fibroblast Activation Protein Death Ligand scFv Fragment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Original work of the authors referred to in this review was supported by Deutsche Krebshilfe, grant no. 107551 and 106235 to H.W. and K.P. as well as by a career fellowship award by the Peter and Traudl Engelhorn Foundation to J.G.

References

  1. 1.
    Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H (2006) A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 84:785–797CrossRefPubMedGoogle Scholar
  2. 2.
    Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, Pfizenmaier K, and Wajant H (2007) Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 14:2021–2034CrossRefPubMedGoogle Scholar
  3. 3.
    Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, and Helfrich W (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281–290CrossRefPubMedGoogle Scholar
  4. 4.
    Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, and Helfrich W (2005) Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380–3388PubMedGoogle Scholar
  5. 5.
    Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, and Helfrich W (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280:10025–10033CrossRefPubMedGoogle Scholar
  6. 6.
    Bremer E, ten Cate B, Samplonius DF, de Leij LF, and Helfrich W (2006) CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107:2863–2870CrossRefPubMedGoogle Scholar
  7. 7.
    Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, and Helfrich W (2008) Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 68:597–604CrossRefPubMedGoogle Scholar
  8. 8.
    Corti A, Fassina G, Marcucci F, Barbanti E, and Cassani G (1992) Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J 284 (Pt 3), 905–910PubMedGoogle Scholar
  9. 9.
    Gerspach J, Muller D, Munkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, and Pfizenmaier K (2006) Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 13:273–284CrossRefPubMedGoogle Scholar
  10. 10.
    Gerspach J, Nemeth J, Munkel S, Wajant H, and Pfizenmaier K (2006) Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 55:1590–1600CrossRefPubMedGoogle Scholar
  11. 11.
    Gerspach J, Wajant H, and Pfizenmaier K (2009) Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 49:241–273Google Scholar
  12. 12.
    Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, and Scheurich P (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793–802CrossRefPubMedGoogle Scholar
  13. 13.
    Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, and Engel J (1998) Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiled-coil alpha-helices. J Biol Chem 273:10602–10608CrossRefPubMedGoogle Scholar
  14. 14.
    Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kuhnle M, Gerspach J, Sterns T, Shnyder SD, Gill JH, Mannel DN, Pfizenmaier K, and Scheurich P (2008) Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 180:8176–8183PubMedGoogle Scholar
  15. 15.
    Lejeune FJ, Lienard D, Matter M, and Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6PubMedGoogle Scholar
  16. 16.
    Muller N, Wyzgol A, Munkel S, Pfizenmaier K, and Wajant H (2008) Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J 275:2296–2304CrossRefPubMedGoogle Scholar
  17. 17.
    O’Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, and Strasser A (2009) Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461:659–663CrossRefGoogle Scholar
  18. 18.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, and Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806–809CrossRefPubMedGoogle Scholar
  19. 19.
    Poiesi C, Albertini A, Ghielmi S, Cassani G, and Corti A (1993) Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods. Cytokine 5:539–545CrossRefPubMedGoogle Scholar
  20. 20.
    Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, and Tykocinski ML (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174:460–474CrossRefPubMedGoogle Scholar
  21. 21.
    Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K, and Wajant H (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 278:32077–32082CrossRefPubMedGoogle Scholar
  22. 22.
    Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K and Gerspach J (2009) Potent antitumoral activity of TRAIL through generation of tumor - targeted single - chain fusion proteins. Cell Death Disease, acceptedGoogle Scholar
  23. 23.
    Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, and Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205–1213CrossRefPubMedGoogle Scholar
  24. 24.
    Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Buhring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, and Helfrich W (2008) Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 57:233–246CrossRefPubMedGoogle Scholar
  25. 25.
    ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, and Helfrich W (2009) A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 23:1389–1397CrossRefPubMedGoogle Scholar
  26. 26.
    Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, and Pfizenmaier K (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20:4101–4106CrossRefPubMedGoogle Scholar
  27. 27.
    Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, and Wajant H (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 14:765–774CrossRefPubMedGoogle Scholar
  28. 28.
    Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, and Wajant H (2009) Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand J Immunol 183:1851–1861CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jeannette Gerspach
    • 1
  • Britta Schneider
    • 1
  • Nicole Müller
    • 2
  • Tina Otz
    • 1
  • Harald Wajant
    • 2
  • Klaus Pfizenmaier
    • 1
  1. 1.Institute of Cell Biology and Immunology, University of StuttgartStuttgartGermany
  2. 2.Department of Molecular Internal MedicineMedical Clinic and Polyclinic II, University of WuerzburgWuerzburgGermany

Personalised recommendations